The dramatic progress in tumour biology and immunology in the past several years has opened new avenues for the treatment and prevention of cancer. One of the great contributions of the immunotherapeutic approaches is an increasing understanding of the immunology of cancer, which is, gradually creating conditions for the development of prophylactic anti-cancer vaccines. Efficient vaccines have been developed and employed for the prophylaxis of two frequent cancers of viral origin, namely cervical cancer and liver cancer. The new knowledge on the interactions between the immune system and the malignant tumors seems to provide means for the development of prophylactic vaccines against cancers developing due to the mutations in the proto-oncogenes converting their products into oncoproteins. According to the present estimates, these cancers form a great majority of human malignancies. Recent evidence has indicated that the immune system recognizes such mutated proteins, and that the development of cancer is due to the failure of the immune system to eliminate neoplastic cells. Followingly, it can be expected that inducing immunity against the mutated epitopes will increase the capacity of the body to deal with the initiated precancerous cells. In the present paper this hypothesis is primarily discussed in the relationship with colorectal cancer (CRC), which seems to be a well-fitting candidate for prophylactic vaccination. CRC is the third most frequent malignancy and the fourth most common cause of cancer mortality. Mutations of two proto-oncogenes, namely RAS and RAF, are involved in the majority of CRC cases and, in addition, they are shared with other human malignancies. Therefore, the strategy to be used for prophylaxis of CRC is discussed together with several other frequent human cancers, namely lung cancer, pancreatic duct cancer and melanoma. The prophylactic vaccines proposed are aimed at the reduction of the incidence of these and, to a lesser extent, some other cancers.

Department of Genetics and Microbiology Faculty of Science Charles University BIOCEV Vestec Czech Republic

Institute of Haematology and Blood Transfusion Emeritus Prague Czech Republic

Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic Prague Czech Republic

Literatura

000      

00000naa a2200000 a 4500

001      

bmc22005943

003      

CZ-PrNML

005      

20220224145608.0

007      

ta

008      

220218s2021 xr f 000 0|eng||

009      

AR

024    7_

$a 10.21101/cejph.a7219 $2 doi

035    __

$a (PubMed)35026062

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xr

100    1_

$a Vonka, Vladimír, $d 1930- $7 jk01150642 $u Institute of Haematology and Blood Transfusion, Emeritus, Prague, Czech Republic

245    10

$a Prophylactic vaccines against cancers of non-infectious origin: a dream or a real possibility / $c V. Vonka, I. Hirsch

504    __

$a Literatura

520    9_

$a The dramatic progress in tumour biology and immunology in the past several years has opened new avenues for the treatment and prevention of cancer. One of the great contributions of the immunotherapeutic approaches is an increasing understanding of the immunology of cancer, which is, gradually creating conditions for the development of prophylactic anti-cancer vaccines. Efficient vaccines have been developed and employed for the prophylaxis of two frequent cancers of viral origin, namely cervical cancer and liver cancer. The new knowledge on the interactions between the immune system and the malignant tumors seems to provide means for the development of prophylactic vaccines against cancers developing due to the mutations in the proto-oncogenes converting their products into oncoproteins. According to the present estimates, these cancers form a great majority of human malignancies. Recent evidence has indicated that the immune system recognizes such mutated proteins, and that the development of cancer is due to the failure of the immune system to eliminate neoplastic cells. Followingly, it can be expected that inducing immunity against the mutated epitopes will increase the capacity of the body to deal with the initiated precancerous cells. In the present paper this hypothesis is primarily discussed in the relationship with colorectal cancer (CRC), which seems to be a well-fitting candidate for prophylactic vaccination. CRC is the third most frequent malignancy and the fourth most common cause of cancer mortality. Mutations of two proto-oncogenes, namely RAS and RAF, are involved in the majority of CRC cases and, in addition, they are shared with other human malignancies. Therefore, the strategy to be used for prophylaxis of CRC is discussed together with several other frequent human cancers, namely lung cancer, pancreatic duct cancer and melanoma. The prophylactic vaccines proposed are aimed at the reduction of the incidence of these and, to a lesser extent, some other cancers.

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    12

$a melanom $7 D008545

650    12

$a nádory slinivky břišní $7 D010190

650    12

$a infekce papilomavirem $7 D030361

650    12

$a vakcíny proti papilomavirům $7 D053918

650    12

$a nádory děložního čípku $7 D002583

650    _2

$a vakcinace $7 D014611

650    12

$a vakcíny $7 D014612

655    _2

$a časopisecké články $7 D016428

700    1_

$a Hirsch, Ivan $7 xx0225178 $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, Vestec, Czech Republic $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic

773    0_

$w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 29, č. 4 (2021), s. 247-258

856    41

$u https://pubmed.ncbi.nlm.nih.gov/35026062 $y Pubmed

910    __

$a ABA008 $b B 1829 $c 562 $y p $z 0

990    __

$a 20220207 $b ABA008

991    __

$a 20220224145555 $b ABA008

999    __

$a ok $b bmc $g 1763623 $s 1157095

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 29 $c 4 $d 247-258 $e 20211231 $i 1210-7778 $m Central European Journal of Public Health $n Cent. Eur. J. Public Health $x MED00001083

LZP    __

$b NLK118 $a Pubmed-20220207